MarketPulse

inflammatory bowel disease

14 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Kymera Therapeutics Advances IBD Pipeline With Promising KT-579 Preclinical Data

Kymera Therapeutics showcases KT-579 preclinical data matching approved IBD therapies ahead of Phase 1 trials in late 2026.
KYMRclinical trialinflammatory bowel disease
BenzingaBenzinga··Vandana Singh

Eli Lilly's Omvoh Shows Durable Long-Term IBD Benefits, Bolstering Pipeline Confidence

Eli Lilly reports durable four-year efficacy data for Omvoh in IBD, with 63.5% ulcerative colitis remission and 92.4% Crohn's response rates, bolstering pipeline confidence.
LLYFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Seres Therapeutics Demonstrates SER-155 Promise in Transplant Patients at ESCMID

Seres Therapeutics presented Phase 1b data for SER-155 showing microbiome shifts and reduced infections in transplant patients at ESCMID Global 2026.
MCRBallogeneic hematopoietic cell transplantationPhase 1b trial
BenzingaBenzinga··Globe Newswire

Spyre Therapeutics Raises $300M in IPO as IBD-Focused Biotech Advances Pipeline

Clinical-stage biotech Spyre Therapeutics launches $300M public offering to fund inflammatory bowel disease drug development, with major investment banks leading.
SYREpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Quotient Therapeutics Lands $2.2B Merck Deal for IBD Drug Discovery Platform

Quotient Therapeutics and Merck partner on IBD drug discovery, with Quotient receiving $20M upfront and up to $2.2B in milestones.
MRKimmunologydrug discovery
The Motley FoolThe Motley Fool··Seena Hassouna

Specialist Biotech Fund's $25.8M Spyre Bet Signals Confidence in Preclinical Pipeline

VR Adviser increased Spyre Therapeutics stake by 1M shares to $120.74M. Stock surged 132% annually, but preclinical risks remain high for retail investors.
SYREbiotech investmentmonoclonal antibodies
GlobeNewswire Inc.GlobeNewswire Inc.··Seres Therapeutics, Inc.

Seres Therapeutics Swings to $5.7M Profit on Nestlé VOWST Sale, Eyes 2026 Clinical Data

Seres Therapeutics swung to $5.7M 2025 profit from $125.8M loss, boosted by Nestlé VOWST sale, with $45.8M cash funding ops through Q3 2026.
MCRBclinical trialinflammatory bowel disease
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Expands Spyre Therapeutics Position as Stock Climbs 63% YoY

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.
ALKSSYRERLAYXENEbiotechbalance sheet strength
GlobeNewswire Inc.GlobeNewswire Inc.··Abivax Sa

Abivax Demonstrates Anti-Fibrotic Potential of Obefazimod at ECCO 2026

Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.
ABVXPhase 3 clinical trialsbiomarkers
BenzingaBenzinga··Vandana Singh

Eli Lilly's Omvoh Demonstrates Three-Year Remission Durability in Crohn's Disease

Eli Lilly's Omvoh shows durable three-year remission in Crohn's disease, with 92.4% of patients maintaining clinical remission and reduced hospitalizations compared to placebo.
LLYFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Teva and Sanofi Report Positive Phase 3 Results for Duvakitug IBD Treatment

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.
SNYTEVAmonoclonal antibodyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Duvakitug Shows Sustained Remission in Phase 2b Trial for Inflammatory Bowel Disease

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi and Teva Report Sustained Efficacy for Duvakitug in IBD Maintenance Study

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi, Teva Report Sustained Efficacy for TL1A Inhibitor in IBD Phase 2b Trial

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease